Arthrosamid is a polyacrylamide hydrogel developed by Contura International Ltd. as a long-lasting intra-articular injection approved in Europe for the treatment of knee osteoarthritis (OA). The treatment has the potential to change the present care pathway for managing osteoarthritis, which affects around one in four adults in Ireland aged over 601 (over 400,000 people)2 and current treatments are not long lasting or involve invasive knee replacement surgery. Despite a large suffering population, there has been very little innovation in the range of osteoarthritis treatments on offer to meaningfully help patients – until now.
Unlocking Knee Gel Injection Insurance: A Step-by-Step Guide to Requirements, Coverage, and Saving on Your Treatment
November 19, 2025
No Comments
Knee gel injections, including traditional hyaluronic acid and newer Arthrosamid treatments, offer effective relief for osteoarthritis pain by lubricating joints. Understanding insurance coverage—such as prior authorisation, coverage criteria, and co-pays—is crucial to managing costs. This guide explains navigating public and private insurance approvals, maximizing chances of coverage through proper documentation, and appealing denials. With rising evidence supporting Arthrosamid’s safety and efficacy, knowing your insurer’s formulary and seeking patient support programs can reduce out-of-pocket expenses. Staying informed helps patients access affordable knee injection therapies and make well-supported health decisions.
